These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24909066)

  • 41. Re: Billis et al.: Does the type of prostatic atrophy influence the association of extent of atrophy in needle biopsies and serum prostate-specific antigen levels? (Urology 2009;74:1111-1115).
    Papatsoris A; Albanis S; Deliveliotis C
    Urology; 2010 May; 75(5):1239; author reply 1240. PubMed ID: 20451754
    [No Abstract]   [Full Text] [Related]  

  • 42. Editorial comment.
    Chong KT
    J Urol; 2009 Oct; 182(4):1348; discussion 1349. PubMed ID: 19683273
    [No Abstract]   [Full Text] [Related]  

  • 43. Editorial comment.
    Lin CC
    J Urol; 2009 Oct; 182(4):1348; discussion 1349. PubMed ID: 19683264
    [No Abstract]   [Full Text] [Related]  

  • 44. Editorial comment.
    van Renterghem KM
    J Urol; 2009 Oct; 182(4):1349; discussion 1349. PubMed ID: 19683263
    [No Abstract]   [Full Text] [Related]  

  • 45. The prostate biopsy.
    Harv Mens Health Watch; 2003 Jul; 7(12):4-7. PubMed ID: 12888462
    [No Abstract]   [Full Text] [Related]  

  • 46. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Editorial comment on: Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels.
    Eggener S
    Eur Urol; 2009 Mar; 55(3):616. PubMed ID: 18639973
    [No Abstract]   [Full Text] [Related]  

  • 48. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen.
    Hambrock T; Somford DM; Hoeks C; Bouwense SA; Huisman H; Yakar D; van Oort IM; Witjes JA; Fütterer JJ; Barentsz JO
    J Urol; 2010 Feb; 183(2):520-7. PubMed ID: 20006859
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Editorial comment.
    Albertsen PC
    Urology; 2012 Oct; 80(4):888. PubMed ID: 22921701
    [No Abstract]   [Full Text] [Related]  

  • 50. Editorial comment.
    Suardi N
    J Urol; 2010 Feb; 183(2):545. PubMed ID: 20006873
    [No Abstract]   [Full Text] [Related]  

  • 51. Editorial comment.
    Benson MC
    J Urol; 2010 Jan; 183(1):131. PubMed ID: 19913248
    [No Abstract]   [Full Text] [Related]  

  • 52. It ain't what you do, it's the way you do it: five golden rules for transforming prostate-specific antigen screening.
    Vickers A; Carlsson S; Laudone V; Lilja H
    Eur Urol; 2014 Aug; 66(2):188-90. PubMed ID: 24411991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy.
    Mishra VC; Motiwala HG
    BJU Int; 2004 May; 93(7):1116-7. PubMed ID: 15142181
    [No Abstract]   [Full Text] [Related]  

  • 54. Editorial comment on: Prostate-specific antigen improves the ability of clinical stage and biopsy gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
    Stenman UH
    Eur Urol; 2007 Oct; 52(4):1074-5. PubMed ID: 17383813
    [No Abstract]   [Full Text] [Related]  

  • 55. Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer.
    Kaplan SA; Lee RK; Chung DE; Te AE; Scherr DS; Tewari A; Vaughan ED
    J Urol; 2012 Sep; 188(3):757-61. PubMed ID: 22818135
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Change in serum prostate specific antigen values in men who had no evidence of prostate cancer on initial biopsy].
    Miyamoto S; Jimbo H; Totsuka Y; Mashimo T; Umeyama T; Uehara H; Shinozaki T
    Hinyokika Kiyo; 1995 Oct; 41(10):767-70. PubMed ID: 8533671
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Some concerns about prostate cancer location, Gleason grade, and postradiation doubling times.
    Stamey TA
    Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):967-8; discussion 972. PubMed ID: 7591913
    [No Abstract]   [Full Text] [Related]  

  • 58. Editorial Comment from Dr Satoh to interpreting a rising prostate-specific antigen after brachytherapy for prostate cancer.
    Satoh T
    Int J Urol; 2013 Feb; 20(2):149. PubMed ID: 22924812
    [No Abstract]   [Full Text] [Related]  

  • 59. Editorial Comment from Dr Stone to interpreting a rising prostate-specific antigen after brachytherapy for prostate cancer.
    Stone NN
    Int J Urol; 2013 Feb; 20(2):148. PubMed ID: 22924786
    [No Abstract]   [Full Text] [Related]  

  • 60. Editorial comment: factor that influence serum prostate-specific antigen levels in terms of maintaining quality within a PSA screening system.
    Ito K
    Eur Urol; 2007 Sep; 52(3):714. PubMed ID: 17849514
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.